Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study

Basit Öğe Kaydı
dc.authoridBEKTAS, MURAT/0000-0002-1788-3837
dc.authorwosidBEKTAS, MURAT/AAT-7121-2020
dc.contributor.authorCakmak, Ramazan
dc.contributor.authorBektas, Murat
dc.date.accessioned2024-05-19T14:40:31Z
dc.date.available2024-05-19T14:40:31Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjective: Patients with COVID-19 accompanying cancer have been reported to have higher morbidity and mortality. In this study, we aimed to evaluate the high -dose high intravenous anakinra treatment response and outcome in patients with COVID-19-associated cytokine storm accompanying cancer. Methods: This retrospective observational study was carried out at a tertiary referral center between September 01, 2021, and February 01, 2022, in Turkey. The study population consisted of two groups: patients receiving high -dose intravenous anakinra and patients treated with standard care. Results: Data from 146 patients in the anakinra group and 114 patients in the control group were analyzed. Malignancy frequency was 11% (n=16) in the anakinra group and 7% (n=8) in the control group. In survival analysis, a significantly lower survival rate was observed in patients with malignancy than those without in the control group (log -rank: p=0.002) and patients with malignancy in the control group compared to the anakinra group (log -rank: p=0.013). However, it did not differ between patients with and without malignancy in the anakinra group (log -rank: p=0.9). Conclusion: In the control group, mortality was higher in patients with malignancy compared to those without malignancy, but not in the anakinra group. Also, mortality was higher in patients receiving SoC compared to anakinra. Intravenous high -dose anakinra treatment is safe and effective in patients with COVID-19 accompanying cancer.en_US
dc.identifier.doi10.36519/idcm.2024.287
dc.identifier.issn2667-646X
dc.identifier.issue1en_US
dc.identifier.pmid38633444en_US
dc.identifier.trdizinid1230454en_US
dc.identifier.urihttps://doi.org10.36519/idcm.2024.287
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1230454
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4973
dc.identifier.volume6en_US
dc.identifier.wosWOS:001185559600009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherDoc Design Informatics Co Ltden_US
dc.relation.ispartofInfectious Diseases and Clinical Microbiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCovid-19en_US
dc.subjectCanceren_US
dc.subjectCytokine Stormen_US
dc.subjectHyperinflammationen_US
dc.subjectAnakinraen_US
dc.titleIndividualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu